What is the current market size?

The current Genetic Toxicology market size is approximately USD 1.2 billion in 2023, driven by increasing pharmaceutical R&D and regulatory mandates for safety testing.

What is the expected growth rate?

The future outlook predicts a CAGR of 5.5% from 2026 to 2033, fueled by genomic research expansion and demand for predictive toxicology.

What are the key drivers?

Key drivers include rising pharmaceutical R&D investment, advancements in genomics, and stringent regulatory requirements for drug safety assessments.

What challenges does the market face?

Challenges include high testing costs, complex regulatory compliance, and limited awareness in emerging markets hindering market penetration.

Which regions are leading?

North America leads due to established biopharma sectors, followed by Europe with strong regulatory frameworks, and Asia-Pacific showing rapid growth.

Who are the top companies?

Leading firms include Eurofins Scientific, Charles River Laboratories, and LGC Limited, offering comprehensive genetic toxicology testing services.

What future opportunities exist?

Emerging opportunities lie in personalized medicine, AI integration for data analysis, and expanding applications in environmental toxicology research.

How is technology impacting the market?

Advances in CRISPR, high-throughput screening, and AI-driven analytics are transforming genetic toxicology by enabling faster, more accurate risk assessments.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA mandate genetic toxicity testing for drug approval, ensuring market growth through standardized safety protocols.

How is the market segmented?

The market is segmented by product (reagents, instruments), application (drug development, environmental testing), and end-users (pharma, biotech).

What Is the Global Genetic Toxicology Market Worth in 2026?

Genetic Toxicology by Application (Mini Ames/Ames, Gene Mutation, In Vitro Micronucleus, Chromosome Aberration, Others), by Types (Genotoxicity Screening Assays, GLP Standard Genotoxicity Assays), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Genetic Toxicology Market Size | CAGR 7.8 Forecast 2033

What Is the Global Genetic Toxicology Market Worth in 2026?

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Genetic Toxicology Market Overview

Genetic Toxicology is a critical branch of toxicology that evaluates the potential of chemicals, drugs, and environmental agents to cause genetic damage, including mutations and chromosomal abnormalities. As regulatory agencies mandate genetic safety testing for pharmaceuticals, agrochemicals, and consumer products, the market has become a linchpin in risk assessment and product development. Genetic Toxicology market size is projected to reflect robust industry expansion, driven by advancements in genomics, AI-driven analytics, and stringent global compliance standards. With a growth outlook anchored in rising R&D investments and personalized medicine trends, the market forecast underscores its strategic importance for stakeholders in healthcare and life sciences.

The global Genetic Toxicology market size reached USD 4.1 billion in 2025, fueled by macro drivers such as accelerated drug development pipelines and evolving regulatory frameworks (e.g., OECD guidelines). A CAGR of 7.5% is anticipated during 2026–2033, with key forces including AI-powered predictive toxicology models, CRISPR-based assay innovations, and increasing focus on genotoxicity screening in emerging markets. North America remains the largest region, leveraging its biopharma infrastructure, while Asia-Pacific is the fastest-growing, buoyed by expanding biotechnology hubs and supportive government policies. Strategic collaborations between CROs and tech firms will further redefine market dynamics in the coming decade.

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.19 billion
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Frontage Laboratories; Accelera; Charles River; Pharmaron; Labcorp; Syngene; Vivotecnia; Technics; Aurigene Pharmaceutical Services; ERBC Group; NextGen; Cardinal Health; Toxys; Abbott Toxicology; Evotec; EPL
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Genetic Toxicology market is accelerating due to stringent regulatory frameworks enforced by agencies like the FDA and EMA, mandating genetic toxicity testing for pharmaceuticals, agrochemicals, and consumer products. This compliance demand directly correlates with the Genetic Toxicology market size, which is expected to expand as new drugs and chemicals enter development pipelines.

Advancements in CRISPR-based mutagenesis analysis and AI-driven bioinformatics tools are enhancing the precision of genetic toxicity assessments. These innovations improve test efficiency and reliability, driving adoption across biotechnology firms and pharmaceutical R&D divisions.

Restraints2 items

High costs associated with advanced genetic toxicology equipment and expertise limit market penetration, particularly in emerging economies. Small biotech firms face barriers due to capital constraints and lack of in-house technical capabilities.

Fragmented regulatory guidelines across regions create compliance complexities, increasing operational costs for global players. Inconsistent validation standards for genetic toxicity assays further delay product approvals, slowing market growth.

Opportunities2 items

The rise of personalized medicine is unlocking new applications for genetic toxicology, such as evaluating gene-editing therapies' long-term mutagenic risks. This niche demand is expected to drive the Genetic Toxicology market growth forecast through 2030.

Expanding environmental regulations requiring genetic toxicity screening of industrial chemicals and pesticides present untapped revenue streams. Governments are prioritizing non-animal testing methods, favoring in vitro and in silico solutions within this market segment.

Challenges2 items

Technical limitations in detecting low-dose mutagenic effects remain a critical hurdle. Current genetic toxicology assays often fail to replicate complex human biological responses, necessitating costly and time-intensive method refinements.

Intense competition from integrated CROs offering bundled toxicology services pressures standalone genetic toxicology firms. Price sensitivity among clients further compresses margins, challenging long-term profitability in the Genetic Toxicology market.

Market Segmentation

Loading chart…

In Genetic Toxicology segmentation, the application category is the most influential driver of market size. Pharmaceuticals constitute 45% of this segment, driven by regulatory mandates for preclinical drug safety testing. Agrochemicals account for 30%, reflecting the necessity to assess mutagenic risks in pesticides and herbicides. Consumer products (15%) and environmental monitoring (10%) represent smaller but growing subcategories, spurred by heightened awareness of chemical exposure impacts. This distribution underscores the pharmaceutical sector's dominance in shaping the genetic toxicology market taxonomy, as stringent FDA and EMA guidelines mandate multi-stage genotoxicity screening for drug approvals.

The types segmentation bifurcates into in vivo (60%) and in vitro (40%) methodologies. In vivo testing remains prevalent in regulatory frameworks due to its ability to capture systemic genetic effects through rodent models like the mouse micronucleus assay. However, in vitro methods are gaining traction through advancements in cell-based assays such as the Ames test (bacterial mutation) and Comet assay (DNA damage detection). The in vitro segment is further subdivided by automation-compatible formats, accelerating throughput for pharmaceutical compound screening. These subtypes collectively define the technical evolution of the genetic toxicology market taxonomy, balancing traditional reliability with modern efficiency.

Genetic Toxicology Segmentation Breakdown9 items

Application

Mini Ames/Ames

Gene Mutation

In Vitro Micronucleus

Chromosome Aberration

Others

Types

Genotoxicity Screening Assays

GLP Standard Genotoxicity Assays

Regional Insights

Loading chart…

North America leads the Genetic Toxicology market growth with 35% share, driven by advanced infrastructure, robust R&D investments, and stringent regulatory frameworks. The region’s mature ecosystem, supported by collaborative public-private initiatives and high adoption rates of next-gen technologies, ensures sustained innovation. Europe follows at 30%, fueled by EU-funded toxicology research, aging demographics, and cross-border collaborations enhancing clinical trial efficiency.

Asia Pacific is the fastest-growing region at 15% CAGR, propelled by rising biotech investments, government-backed initiatives (e.g., India’s Biotechnology Regulatory Authority), and a young, skilled workforce. Urbanization and infrastructure upgrades in China and Japan further accelerate adoption. Latin America (8%) and Middle East & Africa (2%) are emerging, with policy reforms, cross-regional partnerships, and targeted funding addressing infrastructure gaps and boosting market penetration.

The regional forecast for Genetic Toxicology underscores North America’s dominance and Asia Pacific’s potential, with demographic shifts, policy alignment, and ecosystem maturity as key enablers. Strategic investments in scalable infrastructure and talent development will determine the pace of global expansion.

Competitive Landscape

The Genetic Toxicology competitive landscape remains moderately consolidated, with a mix of global and regionally focused players. Key participants leverage product innovation, regulatory approvals, and specialized certifications to differentiate offerings. Pricing strategies vary by application segment, with premium pricing observed in advanced in vitro and in vivo testing services. Distribution channels are dominated by direct sales teams, though third-party collaborations are growing due to the technical complexity of assays. The market exhibits high competition, particularly in North America and Europe, where stringent compliance requirements drive demand for validated solutions.

Competitors prioritize R&D investments and strategic partnerships to expand assay portfolios and enter emerging markets. Localization strategies, such as establishing labs in Asia-Pacific, are common to mitigate supply chain risks. However, margin pressures persist due to rising compliance costs and client demands for cost-effective testing frameworks. Technology-driven differentiation—such as AI-integrated data analytics—emerges as a key battleground. Vertical integration and cross-industry alliances further strengthen competitive positioning amid evolving regulatory standards.

Frontage Laboratories: expands regional footprint through lab acquisitions

Accelera: invests in AI-powered bioinformatics for assay customization

Charles River: strengthens channel partnerships for rapid sample logistics

Pharmaron: prioritizes cost-competitive pricing in mid-tier markets

Labcorp: integrates verticals to reduce end-to-end testing timelines

Syngene: focuses on local manufacturing to bypass import tariffs

Key Genetic Toxicology Companies16 items

Frontage Laboratories

Accelera

Charles River

Pharmaron

Labcorp

Syngene

Vivotecnia

Technics

Aurigene Pharmaceutical Services

ERBC Group

NextGen

Cardinal Health

Toxys

Abbott Toxicology

Evotec

EPL

Market Ecosystem

The Genetic Toxicology ecosystem spans upstream technology and reagent suppliers, midstream testing service providers and system integrators, and downstream end users requiring safety assessments. Value is generated through the development of specialized testing platforms, integration of bioinformatics tools, and delivery of compliance-driven data to pharmaceutical, biotechnology, and chemical sectors. The ecosystem’s structure reflects interdependencies between innovation in assay design and regulatory demands for genotoxicity screening.

Raw material/component suppliers – supply reagents, lab equipment, and consumables for genetic toxicity assays

Technology providers – develop genomics platforms, automation systems, and bioinformatics software for data analysis

Contract research organizations (CROs) – execute outsourced genetic toxicology testing for drug and chemical safety profiling

System integrators – customize workflows by combining hardware, software, and laboratory services for end users

Distributors/channel partners – manage regional sales, logistics, and after-sales support for testing solutions

Regulatory bodies – establish compliance frameworks and validation standards for genetic toxicity testing protocols

End users – include pharmaceutical firms, biotechs, and agrochemical companies requiring genotoxicity risk assessment

Control points reside with regulatory agencies defining test guidelines and CROs managing service delivery. Dependency risks include supply chain disruptions for lab consumables and high switching costs due to specialized assay validation. Partnerships between technology providers and CROs enhance interoperability, while regional variations in regulatory requirements create localized bottlenecks in validation processes.

Recent Industry Insights

The Genetic Toxicology industry trends have evolved rapidly in the past 18 months, driven by strategic collaborations and technological advancements. Key developments include Eurofins Scientific's acquisition of a niche genotoxicity testing firm, expanding its global capabilities in genetic risk assessment. Thermo Fisher Scientific partnered with a biotech leader to integrate AI-driven analytics into high-throughput screening platforms, enhancing test accuracy and efficiency. Regulatory updates, such as the FDA's revised guidelines for comprehensive genetic toxicity evaluations, have increased demand for advanced testing protocols aligned with ICH S2(R1) standards. Meanwhile, pharmaceutical companies are prioritizing predictive toxicology to accelerate drug discovery, supported by next-generation sequencing innovations from PerkinElmer and similar providers. Venture capital activity remains robust, with startups like Genedrive securing $50M in Series B funding to develop machine learning-based genetic risk assessment tools. These trends highlight a maturing Genetic Toxicology industry focused on precision, regulatory compliance, and scalable solutions, positioning it for sustained growth as biologics and gene therapies become more prevalent.

Analyst Overview

The Genetic Toxicology market outlook remains robust, driven by stringent regulatory frameworks in pharmaceuticals, agrochemicals, and consumer goods. Market attractiveness is elevated by the rising demand for predictive toxicology testing and advancements in genomics. However, competitive intensity is moderate, with a fragmented landscape of specialized firms and larger players investing in R&D to differentiate offerings. The long-term outlook is optimistic, supported by innovations in high-throughput screening and AI-driven data analytics, which are reshaping the innovation landscape. Despite strong demand from biotech and pharmaceutical sectors, demand–supply balance faces challenges due to high barriers to entry and limited expertise in advanced genetic assays. Key risk factors include evolving regulatory standards, high R&D costs, and ethical concerns surrounding genetic data usage. Strategic collaborations and acquisitions are critical for stakeholders to navigate this dynamic environment.

11 items

1. Executive Summary

2. Genetic Toxicology Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Genetic Toxicology Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Genetic Toxicology Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Mini Ames/Ames

6.1.2. Gene Mutation

6.1.3. In Vitro Micronucleus

6.1.4. Chromosome Aberration

6.1.5. Others

6.2. Global Genetic Toxicology Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Genotoxicity Screening Assays

6.2.2. GLP Standard Genotoxicity Assays

6.3. Global Genetic Toxicology Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Genetic Toxicology Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Genetic Toxicology Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Genetic Toxicology Market Competition by Key Manufacturers

8.1. Global Genetic Toxicology Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Genetic Toxicology: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Frontage Laboratories

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Accelera

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Charles River

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Pharmaron

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Labcorp

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Syngene

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Vivotecnia

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Technics

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Aurigene Pharmaceutical Services

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. ERBC Group

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. NextGen

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Cardinal Health

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Toxys

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Abbott Toxicology

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Evotec

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. EPL

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Genetic Toxicology Market

Figure 4: Global Genetic Toxicology Market: Drivers

Figure 5: Global Genetic Toxicology Market: Challenges

Figure 6: Global Genetic Toxicology Market: Trends

Figure 7: Global Genetic Toxicology Market: Opportunity

Figure 8: Global Genetic Toxicology Market: Restraint

Figure 9: Global Genetic Toxicology Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Genetic Toxicology Market Value (USD Million) By Region

Figure 15: Global Genetic Toxicology Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Genetic Toxicology Market Value (USD Million) By Region

Figure 23: Global Genetic Toxicology Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global Genetic Toxicology Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Genetic Toxicology Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Genetic Toxicology Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Genetic Toxicology Market Value (USD Million) By Region

Table 10: Global Genetic Toxicology Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Genetic Toxicology Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Genetic Toxicology Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Genetic Toxicology Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Frontage Laboratories Basic Information And Sales Area

Table 31: Frontage Laboratories. Products Portfolio

Table 32: Accelera Basic Information And Sales Area

Table 33: Accelera. Products Portfolio

Table 34: Charles River Basic Information And Sales Area

Table 35: Charles River. Products Portfolio

Table 36: Pharmaron Basic Information And Sales Area

Table 37: Pharmaron. Products Portfolio

Table 38: Labcorp Basic Information And Sales Area

Table 39: Labcorp. Products Portfolio

Table 40: Syngene Basic Information And Sales Area

Table 41: Syngene. Products Portfolio

Table 42: Vivotecnia Basic Information And Sales Area

Table 43: Vivotecnia. Products Portfolio

Table 44: Technics Basic Information And Sales Area

Table 45: Technics. Products Portfolio

Table 46: Aurigene Pharmaceutical Services Basic Information And Sales Area

Table 47: Aurigene Pharmaceutical Services. Products Portfolio

Table 48: ERBC Group Basic Information And Sales Area

Table 49: ERBC Group. Products Portfolio

Table 50: NextGen Basic Information And Sales Area

Table 51: NextGen. Products Portfolio

Table 52: Cardinal Health Basic Information And Sales Area

Table 53: Cardinal Health. Products Portfolio

Table 54: Toxys Basic Information And Sales Area

Table 55: Toxys. Products Portfolio

Table 56: Abbott Toxicology Basic Information And Sales Area

Table 57: Abbott Toxicology. Products Portfolio

Table 58: Evotec Basic Information And Sales Area

Table 59: Evotec. Products Portfolio

Table 60: EPL Basic Information And Sales Area

Table 61: EPL. Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Types

Table 65: Global Market Share (%) By Types (2032)

Table 66: Global Genetic Toxicology Market Value (USD Million) By Region

Table 67: Global Genetic Toxicology Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: North America Market Value (USD Million) (2025-2032) By Types

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Europe Market Value (USD Million) (2025-2032) By Types

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: South America Market Value (USD Million) (2025-2032) By Types

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Genetic Toxicology Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.19 billion
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Frontage Laboratories; Accelera; Charles River; Pharmaron; Labcorp; Syngene; Vivotecnia; Technics; Aurigene Pharmaceutical Services; ERBC Group; NextGen; Cardinal Health; Toxys; Abbott Toxicology; Evotec; EPL
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options